1 December 2023 in Journal of Chemical Information and Modeling
15 August 2025 in bioRxiv
Predicting protein stability change upon mutation is critical for protein engineering, yet remains limited by the modeling assumptions of physics-based methods and the generalization bottlenecks of data-driven approaches. We present ProStab, a deep learning framework that integrates sequence- and structure-based information, including the mutation-aware sequence embeddings from protein language models and the geometric features extracted via an inverse folding model. Trained on the large-scale Megascale dataset, ProStab demonstrates strong performance across diverse test sets and robust generalization across distribution shifts between the training and test sets. In head-to-head comparisons, ProStab outperforms all state-of-the-art methods with consistently higher Spearman correlation and precision. To evaluate its practical utility, we experimentally validated ProStab-predicted mutations on the model enzyme transaminase. Among the 16 successfully expressed variants, 4 exhibited improved thermal stability. Remarkably, the 1st top-ranked predicted mutation yielded the highest observed enzymatic activity, retaining three-fold that of the wild type after 10 minutes at 40 °C. To facilitate broader application, a publicly accessible web server has been developed. We envisage that ProStab provides a scalable and accurate platform for intelligent protein stability design.
2 September 2025 in Interdisciplinary Sciences: Computational Life Sciences
9 April 2026 in Chemical Science
CycDiff-DPO uses preference-aligned diffusion to design target-specific macrocyclic peptides with enhanced membrane permeability, balancing binding competence and cell permeability in one framework.
10 December 2025 in IEEE Journal of Biomedical and Health Informatics
Accurate drug-target interaction prediction is vital for drug discovery and optimization. Traditional experimental methods, while effective, are time-intensive and costly. HyperGCN-DTI, a novel framework that explicitly advances beyond existing models such as CHL-DTI and HHDTI by leveraging hypergraph neural networks with a multimodal feature fusion strategy. While exsiting methods primarily focuses on low-order graph representations and fixed heterogeneous network structures, HyperGCN-DTI incorporates richer multimodal fused features including embeddings from pretrained language models and diverse biological networks and build robust hypergraphs that capture high-order multi-entity relationships within drug-target pairs. This dual-channel architecture effectively captures both local topological connections and higher-order structural dependencies. HyperGCN-DTI outperforms state-of-the-art DTI prediction models across multiple datasets and remains robust under imbalanced and large-scale real-world datasets, demonstrating its superior predictive power. The model demonstrates significant improvements when using multimodal features and hypergraph-based message passing, with sensitivity analysis confirming stability across hyperparameter variations. Top-ranked predictions are validated through biomedical literature and molecular docking, underscoring the reliability and practical relevance of our approach. HyperGCN-DTI is the first DTI prediction model to jointly integrate such a wide range of heterogeneous information sources with hypergraph representation, significantly enhancing accuracy and robustness, particularly in sparse or noisy settings. The proposed model offers a powerful and generalizable tool for accelerating drug development and target identification.